IL-12 is a promising tumor immunotherapy, but its therapeutic use is limited by acute NK cell-associated toxicity. Koliesnik et al. report the discovery of STK-026, an IL-12-Fc partial agonist that preferentially drives effector function in T cells, which express high levels of IL-12 receptors, and avoids NK cell-associated toxicity.